Drugmakers Oppose Levaquin, Cipro, Avelox MDL

Manufacturers of fluoroquinolone drugs Levaquin, Cipro and Avelox—strong prescription antibiotics that have been linked to permanent nerve damage—who are facing mounting lawsuits throughout the federal court system are opposing plaintiffs’ motions to centralize proceedings. Plaintiffs of the two dozen cases pending in several U.S. District Courts across the country called for consolidation of their cases into a multi-district litigation, or “MDL.”  An MDL gathers similar cases together under one umbrella to expedite pretrial events while being presided over by one judge. Levaquin, Cipro and Avelox have all been linked to peripheral neuropathy in patients who took the drug to fight minor infections—side effects patients claim that Bayer and Janssen Pharmaceuticals did not adequately warn them about on the drugs’ labels.

Real Time Analytics